These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 18219321)

  • 1. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.
    Adams C; Totpal K; Lawrence D; Marsters S; Pitti R; Yee S; Ross S; Deforge L; Koeppen H; Sagolla M; Compaan D; Lowman H; Hymowitz S; Ashkenazi A
    Cell Death Differ; 2008 Apr; 15(4):751-61. PubMed ID: 18219321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
    Jin H; Yang R; Ross J; Fong S; Carano R; Totpal K; Lawrence D; Zheng Z; Koeppen H; Stern H; Schwall R; Ashkenazi A
    Clin Cancer Res; 2008 Dec; 14(23):7733-40. PubMed ID: 19047100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
    Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
    Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo.
    Lei G; Xu M; Xu Z; Gu L; Lu C; Bai Z; Wang Y; Zhang Y; Hu H; Jiang Y; Zhao W; Tan S
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28953230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth.
    Qiu Y; Zhang Z; Shi J; Liu S; Liu Y; Zheng D
    IUBMB Life; 2012 Sep; 64(9):757-65. PubMed ID: 22815059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.
    Brünker P; Wartha K; Friess T; Grau-Richards S; Waldhauer I; Koller CF; Weiser B; Majety M; Runza V; Niu H; Packman K; Feng N; Daouti S; Hosse RJ; Mössner E; Weber TG; Herting F; Scheuer W; Sade H; Shao C; Liu B; Wang P; Xu G; Vega-Harring S; Klein C; Bosslet K; Umaña P
    Mol Cancer Ther; 2016 May; 15(5):946-57. PubMed ID: 27037412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer.
    Zinonos I; Labrinidis A; Lee M; Liapis V; Hay S; Ponomarev V; Diamond P; Zannettino AC; Findlay DM; Evdokiou A
    Mol Cancer Ther; 2009 Oct; 8(10):2969-80. PubMed ID: 19808976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.
    Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
    Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
    Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
    Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.
    Huet HA; Growney JD; Johnson JA; Li J; Bilic S; Ostrom L; Zafari M; Kowal C; Yang G; Royo A; Jensen M; Dombrecht B; Meerschaert KR; Kolkman JA; Cromie KD; Mosher R; Gao H; Schuller A; Isaacs R; Sellers WR; Ettenberg SA
    MAbs; 2014; 6(6):1560-70. PubMed ID: 25484045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation.
    Qiao C; Hu M; Guo L; Lv M; Lin Z; Geng J; Lang X; Li X; Li Y; Ma Y; Feng J; Shen B
    BMC Immunol; 2012 Jul; 13():40. PubMed ID: 22788777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors.
    Camidge DR
    Expert Opin Biol Ther; 2008 Aug; 8(8):1167-76. PubMed ID: 18613768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.
    Milutinovic S; Kashyap AK; Yanagi T; Wimer C; Zhou S; O'Neil R; Kurtzman AL; Faynboym A; Xu L; Hannum CH; Diaz PW; Matsuzawa S; Horowitz M; Horowitz L; Bhatt RR; Reed JC
    Mol Cancer Ther; 2016 Jan; 15(1):114-24. PubMed ID: 26516157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.
    Wilson NS; Yang B; Yang A; Loeser S; Marsters S; Lawrence D; Li Y; Pitti R; Totpal K; Yee S; Ross S; Vernes JM; Lu Y; Adams C; Offringa R; Kelley B; Hymowitz S; Daniel D; Meng G; Ashkenazi A
    Cancer Cell; 2011 Jan; 19(1):101-13. PubMed ID: 21251615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
    Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ
    Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
    Buchsbaum DJ; Zhou T; Grizzle WE; Oliver PG; Hammond CJ; Zhang S; Carpenter M; LoBuglio AF
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3731-41. PubMed ID: 14506165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
    Straughn JM; Oliver PG; Zhou T; Wang W; Alvarez RD; Grizzle WE; Buchsbaum DJ
    Gynecol Oncol; 2006 Apr; 101(1):46-54. PubMed ID: 16271751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a bioassay as a measure of drozitumab-mediated apoptosis induced by soluble Fc gamma receptors.
    Shim J; Huang A; Miller AS
    J Immunol Methods; 2017 Sep; 448():26-33. PubMed ID: 28506821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting a novel N-terminal epitope of death receptor 5 triggers tumor cell death.
    Zhang P; Zheng Y; Shi J; Zhang Y; Liu S; Liu Y; Zheng D
    J Biol Chem; 2010 Mar; 285(12):8953-66. PubMed ID: 20106985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of ATF3 in synergistic cancer cell killing by a combination of HDAC inhibitors and agonistic anti-DR5 antibody through ER stress in human colon cancer cells.
    Liu J; Edagawa M; Goshima H; Inoue M; Yagita H; Liu Z; Kitajima S
    Biochem Biophys Res Commun; 2014 Mar; 445(2):320-6. PubMed ID: 24530917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.